Multicenter phase ii study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)

Table 5 Multi-factor analysis of risk factors for chronic graft-versus-host disease

Variable	N	cGVHD			Extensive cGVHD
Variable	N	HR	95% CI	P	HR	95% CI	P
Age for recipients, years
<40	286	1.00			1.00
≥40	180	1.24	0.96-1.59	0.093	1.35	0.97-1.87	0.072
Donor-recipient gender
Other	336	1.00			1.00
Female → Male	130	1.35	1.04-1.75	0.026	1.67	1.20-2.34	0.002
Conditioning regimen
BuCy	326	1.00			1.00
TBICy	23	0.62	0.30-1.24	0.175	0.91	0.20-1.50	0.244
BuFlu	116	1.38	1.05-1.81	0.020	1.69	1.20-2.39	0.003
aGVHD
No	332	1.00			1.00
Yes	134	1.73	1.34-2.23	0.000	1.94	1.39-2.69	0.000

aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; Flu, fludarabin.

ISSN: 1756-8722